Neurocrine Biosciences (NBIX) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 29.4% versus a gain of 1.6%. Over five years, NBIX leads with a +35.1% price change compared with +31.3% for TAK. Takeda Pharmaceutical is the larger company by market cap ($59.42 billion vs $14.29 billion), about 4.2 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.8x vs 35.1x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1075.27%, while Neurocrine Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | TAK |
|---|---|---|
| Share price | $140.62 | $18.60 |
| Market cap | $14.29B | $59.42B |
| 1-day change | -0.45% | +0.43% |
| YTD return | -0.41% | +18.79% |
| 1-year return | +1.56% | +29.42% |
| 5-year return | +35.12% | +31.35% |
| P/E ratio (TTM) | 20.62 | — |
| Forward P/E | 11.84 | 35.09 |
| EPS (TTM) | $6.82 | $-0.34 |
| Dividend yield | 0.00% | 1075.27% |
| Annual dividend | $0.00 | $200.00 |
| Revenue (latest FY) | $2.86B | — |
| Revenue growth (YoY) | +21.45% | — |
| Net income (latest FY) | $478.60M | — |
| Gross margin | 98.18% | — |
| Operating margin | 21.64% | — |
| Net margin | 16.73% | — |
| 52-week high | $186.12 | $19.10 |
| 52-week low | $122.14 | $12.99 |
| Distance from 52-week high | -24.45% | -2.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +47.41% | +18.06% |
| Average volume | 1.30M | 3.04M |
| Shares outstanding | 101.65M | 3.19B |
| Employees | 2,500 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 4.2 times larger than Neurocrine Biosciences by market value ($59.42B vs $14.29B).
- TAK has outperformed NBIX by 27.9 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1075.27% vs 0.00%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
NBIX vs TAK FAQ
Which is bigger, Neurocrine Biosciences or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.42B compared with $14.29B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, NBIX or TAK?
TAK returned +29.42% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Neurocrine Biosciences or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1075.27%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Neurocrine Biosciences and Takeda Pharmaceutical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences and Biotechnology: Pharmaceutical Preparations for Takeda Pharmaceutical.